id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3278-0012,FDA,FDA-2019-E-3278,Notice of Final Determination,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T17:47:43Z,,0,0,090000648648caf1
FDA-2019-E-3278-0013,FDA,FDA-2019-E-3278,Response to Request for Information Pursuant to 37 C.F.R. 1.750,Other,Letter(s),2024-03-14T04:00:00Z,2024,3,2024-09-18T04:00:00Z,,2024-09-18T18:42:43Z,,0,0,090000648648cbb3
FDA-2019-E-3278-0011,FDA,FDA-2019-E-3278,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2024-03-13T04:00:00Z,2024,3,2024-03-13T04:00:00Z,,2024-03-13T17:59:00Z,,0,0,09000064864795a4
FDA-2019-E-3278-0010,FDA,FDA-2019-E-3278,Requirement for Information Letter from U.S. Patent and Trademark Office to Merck & Co. Inc.,Other,Letter(s),2024-02-28T05:00:00Z,2024,2,2024-02-28T05:00:00Z,,2024-03-13T17:52:22Z,,0,0,090000648641eab3
FDA-2019-E-3278-0009,FDA,FDA-2019-E-3278,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-10T05:00:00Z,2024,1,2024-01-10T05:00:00Z,,2024-03-13T17:52:04Z,,0,0,0900006486389509
FDA-2019-E-3278-0008,FDA,FDA-2019-E-3278,Determination of Regulatory Review Period for Purposes of Patent Extension; DELSTRIGO—New Drug Application 210807,Notice,Determinations,2023-08-04T04:00:00Z,2023,8,2023-08-04T04:00:00Z,2023-10-04T03:59:59Z,2023-08-04T15:49:29Z,2023-16606,0,0,0900006485dc5b38
FDA-2019-E-3278-0007,FDA,FDA-2019-E-3278,"Determination of Regulatory Review Period for Purposes of Patent Extension; PIFELTRO—New Drug
Application 210806",Notice,Determinations,2023-08-04T04:00:00Z,2023,8,2023-08-04T04:00:00Z,2023-10-04T03:59:59Z,2023-08-04T15:49:17Z,2023-16607,0,0,0900006485dbe4a8
FDA-2019-E-3278-0005,FDA,FDA-2019-E-3278,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-07-14T04:00:00Z,2023,7,2023-07-14T04:00:00Z,,2023-07-14T18:55:02Z,,0,0,0900006485cb38f4
FDA-2019-E-3278-0006,FDA,FDA-2019-E-3278,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-07-14T04:00:00Z,2023,7,2023-07-14T04:00:00Z,,2023-07-14T21:16:05Z,,0,0,0900006485cb551c
FDA-2019-E-3278-0004,FDA,FDA-2019-E-3278,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T21:26:33Z,,0,0,090000648555fb6a
FDA-2019-E-3278-0003,FDA,FDA-2019-E-3278,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-02T05:00:00Z,2019,12,2019-12-02T05:00:00Z,,2019-12-02T18:24:43Z,,0,0,09000064841d9231
FDA-2019-E-3278-0002,FDA,FDA-2019-E-3278,"Patent Extension Application from Merk & Co., Inc. (on behalf of Merck Canada Inc.)",Other,Application,2019-07-08T04:00:00Z,2019,7,2019-07-08T04:00:00Z,,2019-07-09T12:45:15Z,,0,0,0900006483d6a50a
FDA-2019-E-3278-0001,FDA,FDA-2019-E-3278,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2019-07-08T04:00:00Z,2019,7,2019-07-08T04:00:00Z,,2019-07-08T19:57:00Z,,0,0,0900006483d6a509